La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BrightGene Bio-Medical Technology Résultats passés
Passé contrôle des critères 2/6
BrightGene Bio-Medical Technology has been growing earnings at an average annual rate of 17.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 19.4% per year. BrightGene Bio-Medical Technology's return on equity is 6.8%, and it has net margins of 16.1%.
Informations clés
17.3%
Taux de croissance des bénéfices
15.0%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 19.4% |
| Rendement des fonds propres | 6.8% |
| Marge nette | 16.1% |
| Prochaine mise à jour des résultats | 24 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Ventilation des recettes et des dépenses
Comment BrightGene Bio-Medical Technology gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 1,215 | 196 | 180 | 265 |
| 31 Dec 23 | 1,180 | 202 | 181 | 249 |
| 30 Sep 23 | 1,160 | 234 | 178 | 232 |
| 30 Jun 23 | 1,104 | 237 | 166 | 217 |
| 31 Mar 23 | 1,074 | 250 | 186 | 213 |
| 31 Dec 22 | 1,017 | 240 | 183 | 207 |
| 30 Sep 22 | 1,076 | 265 | 193 | 193 |
| 30 Jun 22 | 1,074 | 249 | 187 | 189 |
| 31 Mar 22 | 1,112 | 256 | 170 | 194 |
| 31 Dec 21 | 1,052 | 244 | 156 | 173 |
| 30 Sep 21 | 1,023 | 225 | 145 | 164 |
| 30 Jun 21 | 961 | 203 | 130 | 154 |
| 31 Mar 21 | 844 | 184 | 109 | 130 |
| 31 Dec 20 | 785 | 170 | 98 | 138 |
| 30 Sep 20 | 700 | 169 | 92 | 130 |
| 30 Jun 20 | 596 | 143 | 88 | 127 |
| 31 Mar 20 | 544 | 129 | 86 | 126 |
| 31 Dec 19 | 503 | 111 | 84 | 121 |
| 30 Sep 19 | 466 | 96 | 76 | 106 |
| 30 Jun 19 | 445 | 83 | 98 | 147 |
| 31 Mar 19 | 410 | 74 | 80 | 117 |
| 31 Dec 18 | 408 | 73 | 66 | 92 |
| 31 Dec 17 | 317 | 46 | 53 | 77 |
| 31 Dec 16 | 201 | 17 | 46 | 51 |
Des revenus de qualité: 688166 has high quality earnings.
Augmentation de la marge bénéficiaire: 688166's current net profit margins (16.1%) are lower than last year (23.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 688166's earnings have grown by 17.3% per year over the past 5 years.
Accélération de la croissance: 688166's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 688166 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 688166's Return on Equity (6.8%) is considered low.